Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
The Korea Institute Of Oriental Medicine currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Both of these actions are concentrated within 1 distinct art unit, which indicates a focused examination environment for the institute's current patent applications. This concentration allows for a specialized prosecution strategy within this specific technical field.
The workload is split between 2 distinct examiners. This arrangement means that while the applications are in the same art unit, they are being evaluated by different individuals with potentially different interpretive styles. Managing these examiners within the identified art unit allows for a varied approach to addressing office actions.
INAM, SAHAR is the busiest examiner for this portfolio, currently handling 1 pending office action. As this examiner is responsible for a portion of the pending actions, the workload is balanced between the identified busiest examiner and the other distinct examiner involved. This distribution minimizes the impact of any single examiner's specific procedural preferences on the overall portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| SPAINE, ROBERT FRANKLIN | 1 | 75.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18723290 | USE OF ARISTOLOXAZINE C HAVING ANTICANCER ACTIVITY | INAM, SAHAR | — |
| 18722979 | COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING RESPIRATORY DISEASE COMPRISING LYSIMACHIA MAURITIANA EXTRACT AS EFFECTIVE COMPONENT | SPAINE, ROBERT FRANKLIN | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18723290 | USE OF ARISTOLOXAZINE C HAVING ANTICANCER ACTIVITY | INAM, SAHAR | — | §103§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18722979 | COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING RESPIRATORY DISEASE COMPRISING LYSIMACHIA MAURITIANA EXTRACT AS EFFECTIVE COMPONENT | SPAINE, ROBERT FRANKLIN | 1655 | §103§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial